Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b1025ba0762fe27f2e8e2ff7121e9d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4134be174a6690f8eb82690663d01dce |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-38 |
filingDate |
2009-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2011-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_470e32a0e8b10f4f5fbc75c593d5faed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eef9fbb670321641f1a31fc05bc6b642 |
publicationDate |
2011-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8063031-B2 |
titleOfInvention |
Implants and methods for treating inflammation-mediated conditions of the eye |
abstract |
Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10076526-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9629826-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11185441-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8242099-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013281417-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10702539-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10206934-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9192511-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9012437-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9592242-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9283178-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012252771-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9775849-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8778381-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8828446-B2 |
priorityDate |
2000-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |